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A Missense Mutation in the Aggrecan C-type Lectin
Domain Disrupts Extracellular Matrix Interactions
and Causes Dominant Familial Osteochondritis Dissecans
Eva-Lena Stattin,1 Fredrik Wiklund,2 Karin Lindblom,3 Patrik O¨nnerfjord,3 Bjo¨rn-Anders Jonsson,1
Yelverton Tegner,4 Takako Sasaki,5 Andre´ Struglics,3 Stefan Lohmander,3 Niklas Dahl,6 Dick Heinega˚rd,3
and Anders Aspberg7,*
Osteochondritis dissecans is a disorder in which fragments of articular cartilage and subchondral bone dislodge from the joint surface.
We analyzed a ﬁve-generation family in which affected members had autosomal-dominant familial osteochondritis dissecans.
A genome-wide linkage analysis identiﬁed aggrecan (ACAN) as a prime candidate gene for the disorder. Sequence analysis of ACAN re-
vealed heterozygosity for a missensemutation (c.6907G> A) in affected individuals, resulting in a p.V2303M amino acid substitution in
the aggrecan G3 domain C-type lectin, which mediates interactions with other proteins in the cartilage extracellular matrix. Binding
studies with recombinant mutated and wild-type G3 proteins showed loss of ﬁbulin-1, ﬁbulin-2, and tenascin-R interactions for the
V2303M protein. Mass spectrometric analyses of aggrecan puriﬁed from patient cartilage veriﬁed that V2303M aggrecan is produced
and present in the tissue. Our results provide a molecular mechanism for the etiology of familial osteochondritis dissecans and show
the importance of the aggrecan C-type lectin interactions for cartilage function in vivo.Introduction
The skeletal disorder osteochondritis dissecans is deﬁned
as a separation of cartilage and subchondral bone from
the surrounding tissue and primarily affects the knee,
ankle, and elbow joints.1 Most cases of osteochondritis dis-
secans are sporadic, with a prevalence of knee osteochon-
dritis of 15–29 per 100,000,2 and its etiology remains
unclear. Familial osteochondritis dissecans (MIM 165800)
is a rare disorder involving disturbed chondroskeletal
development, disproportionate growth, and deformation
of the skeleton.3–7 The familial osteochondritis dissecans
phenotype presents as multiple osteochondritic lesions
in knees and/or hips and/or elbows (Figures 1A–1D),
disproportionate short stature, and early osteoarthritis
(OA).4
Aggrecan is a major cartilage component and confers re-
silience to the tissue. The extreme ﬁxed charge density of
the proteoglycan molecule creates a high osmotic activity
and swelling pressure retained by the cartilage collagen
network, making joint cartilage ideal for resisting compres-
sive load with minimal deformation.8 This large proteo-
glycan consists of globular domains ﬂanking an elongated
domain substituted with over 100 chondroitin sulfate and
additional keratan sulfate glycosaminoglycan chains and
oligosaccharides (Figure 2A).9 The globular domains
mediate interactions with other components of the extra-
cellular matrix (ECM); the N-terminal G1 domain binds
to hyaluronan,10 and the C-terminal G3 domain binds1Department of Medical Biosciences, Medical and Clinical Genetics, Umea˚ Un
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(CLD).11–15 Data from a mutation in the chick aggrecan
gene causing nanomelia suggests that the CLD repeat
may also be involved in the secretion of aggrecan from
chondrocytes.16
In the present study, we performed genome-wide linkage
analyses on a ﬁve-generation family with hereditary osteo-
chondritis dissecans. We identiﬁed heterozygosity for
a missense mutation, p.V2303M in the aggrecan CLD.
Biochemical analysis using recombinant proteins showed
that the mutation led to loss of interaction with known
ECM protein ligands, and mass spectrometry analysis of
patient cartilage extract veriﬁed that the mutated aggrecan
proteoglycan was produced.Methods
Clinical Information
A ﬁve-generation family from northern Sweden with autosomal-
dominantly inherited osteochondritis dissecans was studied.4 In
total, the study comprised 53 family members, including 15
affected individuals. Investigations included medical history,
physical examination, MRI or radiography of knees, hips and
hands in some individuals, and blood collection for DNA extrac-
tion. The case deﬁnition was osteochondritis dissecans in at least
one joint. Fifteen family members were previously described in
detail.4 In this study, four additional family members were
included. Two of these (pedigree numbers V:5 and V:7) developed
osteochondritis dissecans in the knees at the age of 13 years,iversity Hospital, 90185 Umea˚, Sweden; 2Medical Epidemiology and Biosta-
cal Sciences Lund, Lund University, 22184 Lund, Sweden; 4Department of
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whereas the remaining two family members (pedigree numbers
IV:5 and IV:18) showed a milder phenotype but were found to
carry the familial haplotype and mutation. The study was con-
ducted after approval by the Research Ethics Committee of Umea˚
University Hospital, Sweden, and informed consent was obtained
from each participating family member or that person’s legal
guardian.Genome-wide Scan
Genomic DNA from 53 participants including healthy parents and
siblings was prepared from white blood cells. In brief, buffy-coat
blood cells were lysed, and nuclei were isolated through centrifu-
gation. After denaturation, proteinase K digestion, and centrifuga-
tion, the DNAwas precipitated from the supernatant with alcohol,
washed, air-dried, and dissolved in TE buffer. Samples from 38
family members were analyzed with 400 microsatellite markers
spanning all autosomes with an average spacing of 10 cM (Linkage
Mapping Set 10 cM version 2.5, Applied Biosystems). Multiplex
PCR reactions were performed according to the manufacturer’s
instructions. The PCR products were separated on 36 cm capillary
arrays by the use of POP-4 polymer in an ABI PRISM 3170 DNA
sequencer. Genotypes were analyzed manually, and linkage was
calculated with MCLINK (Myriad Genetics),17 which utilizes the
robust multipoint linkage statistic TLOD proposed by Goring
and Terwilliger.18 An autosomal-dominant inheritance model was
used in the analysis, and the disease allele frequency was set to
0.0001. Affected cases were assumed to be carriers of the disease
allele, and the phenocopy rate was assumed to be 15%. All unaf-
fected individuals were given an unknown phenotype. Marker
allele frequencies were estimated empirically from all 38 individ-
uals genotyped.ACAN Gene Sequencing
The ACAN gene [MIM 155760] is located on chromosome 15q26
and consists of 19 exons ranging in size from 77–4224 bp.19 The
19 exons and intron-exon boundaries of the ACAN gene were
ampliﬁed by PCR (see Table 1 for primers used). Samples from
two affected and two unaffected family members were analyzed
by bidirectional sequencing with an ABI PRISM 3170 DNA
sequencer (Applied Biosystems).PCR-dHPLC Analysis
To evaluate the presence of the c.6907G > A mutation in 115
Swedish army recruits, we used dHPLC20 (Transgenomic Wave
3500HT system). We realized optimal heteroduplex formations
by denaturing PCR products at 95C for 5 min and gradually cool-Figure 1. Radiographic Phenotype of Familial Osteochondritis Dis
(A–D) MRI (A) and radiographs (B–D) from a 14-year-old male patien
chondritic lesions (arrows) at the lateral aspect of themedial femoral c
elbow (C and D).
(E) Genome-wide scan showing linkage to chromosome 15q in a fam
cans over ﬁve generations.
(F) Multipoint analysis, with the polymorphic markers D15S128, D
D15S117, D15S153, D15S131, D15S205, D15S127, D15S130, and D
D15S127.
(G) Haplotype showing polymorphic marker alleles from chromosom
(from top to bottom): D15S117, D15S153, D15S131, D15S205, D15S
by the open boxes within the haplotypes below the symbols. Fille
proband, and asterisks denote individuals examined (by E.-L. S.). In
III have been veriﬁed through archived medical journals and radiogr
128 The American Journal of Human Genetics 86, 126–137, Februarying them to 24C over a period of 60min. Analysis of a 340 bp am-
plicon across themissensemutation was performed on a wild-type
sample, a positive control, and 230 Swedish control chromo-
somes. Five microliters of PCR products of the heteroduplex/
homoduplex mixture was loaded on a DNASep HT Cartridge
(Transgenomics, Omaha, USA) with an automatic sample injector
Model HI/L 7100. PCR products were eluted from the columnwith
an acetonitrile gradient in 0.1 M triethylamine acetate buffer
(pH 7) at a constant ﬂow rate of 1.5 ml/min. Wavemaker 4.1 soft-
ware (Transgenomic, Omaha, NE) was used for calculating the
acetonitrile concentration during the gradient and the optimal
partially denaturing temperature (Tm) for the amplicon, as well
as for evaluating the results. The Tm of this amplicon was deter-
mined as 62.5C.
Recombinant Proteins
The production and puriﬁcation of recombinant domain II of
ﬁbulin-121 and ﬁbulin-2,22 full-length tenascin-R,23 ﬁbronectin
type III repeats 3–5 of tenascin-R,24 alkaline phosphatase-tagged
aggrecan C-type lectin,12 and the wild-type aggrecan G3 splice
variants Lt, LCt, and E1E2LCt23 have been described. The corre-
sponding aggrecan G3 variants carrying the familial osteochon-
dritis dissecans V2303M mutation were produced by site-directed
mutagenesis of the expression plasmids (QuikChange, Stratagene)
with the primers 50-CTCGTGCCAGATCATGACCATACAGTCCTC
TCCAGC-30 and 50-GCTGGAGAGGACTGTATGGTCATGATCTG
GCACGAG-30, transfection into 293 c18 cells (ATCC CRL-
10852), selection with hygromycin, and puriﬁcation of the re-
combinant proteins from the cell culture medium via nickel
chelation afﬁnity chromatography followed by MonoQ ion
exchange chromatography, as described for the wild-type
constructs.23 For use in BIAcore experiments, proteins were
further puriﬁed by gel ﬁltration on a Superdex 75 PC3.2/30
column in a SMART chromatography system (Pharmacia) using
BIAcore running buffer (10 mM HEPES-HCl, 150 mM NaCl,
2 mM CaCl2, and 0.005% P20 [pH 7.5]) as eluent. To verify the
Val-to-Met mutation, we digested the resulting recombinant
proteins with trypsin and analyzed peptide masses by MALDI-
TOF mass spectrometry as described.25
Analysis of Protein Interactions
Solid-Phase Competition Binding Experiments
Microtiter wells (NUNC Maxisorp, Nalge, Denmark) were coated
with 2.5 mg/ml tenascin-R in 50 mM sodium carbonate buffer
(pH 9.5) at 4C overnight. The wells were washed with TTBS-Ca
(5 mM CaCl2, 150 mM NaCl, 0.05% Tween 20, and 50 mM Tris-
HCl [pH 7.4]), incubated with blocking solution (3% BSA in TTBS)secans and Gene Linkage with Chromosome 15q
t with familial osteochondritis dissecans. The image shows osteo-
hondyle in the knee (A and B) and at the humeral capitellum in the
ily displaying autosomal-dominant familial osteochondritis disse-
15S1002, D15S165, D15S1007, D15S1012, D15S994, D15S978,
15S120, resulting in a maximal lod score of 6.36 at marker locus
e 15q in familial osteochondritis dissecans. Themarkers shown are
127, D15S130, and D15S120. The disease haplotype is highlighted
d symbols represent affected individuals, the arrow indicates the
addition, the diagnoses of individuals 6, 8, and 11 in generation
aphs.
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Figure 2. A Missense Mutation in the Aggrecan C-type Lectin
Repeat Is Present in Patients with Familial Osteochondritis Disse-
cans
(A) Organization of the ACAN gene (top), domain structure of the
aggrecan core protein (middle), and proteoglycan (bottom).
(B) Sequence analysis from individuals affected by familial osteo-
chondritis dissecans (middle and bottom traces), but not from
The Americafor 1 hr at room temperature, andwashedwith BSA/TTBS-Ca (0.3%
BSA in TTBS-Ca). Wild-type or V2303M aggrecan G3 domain
variant E1E2LCt protein was loaded into the wells at ﬁnal concen-
trations of 0.3–1000 nM, together with 1 mg/ml (14 nM) alkaline-
phosphatase-tagged rat aggrecan lectin domain, and incubated for
1hr. After extensivewashingwithTTBS-Ca,1mg/mlp-nitrophenyl
phosphate (in 5 mMMgCl2, 100 mM NaCl, and 100 mM Tris-HCl
[pH 9.5]) was added, and the absorbance was measured at 405 nm
after a 3 hr incubation. Sigmoidal dose-response curves were ﬁtted
to the data by nonlinear regression, and IC50 values were deter-
mined with Prism 3.02 for Windows (GraphPad software).
Surface Plasmon Resonance Measurements
Three different extracellular matrix ligands of the aggrecan G3
domain, i.e., tenascin-R, ﬁbulin-1, and ﬁbulin-2, were diluted
with 10 mM sodium acetate (pH 4.0) and immobilized in
different ﬂow cells of CM5 sensor chips (BIAcore). Immobiliza-
tion levels were between 400 and 750 resonance units. As a
control for changes in the sample refraction index, a blank
ﬂow cell was subjected to the immobilization procedure without
added protein. For afﬁnity measurements, binding and dissocia-
tion were monitored in a BIAcore 2000 instrument (BIAcore).
The puriﬁed wild-type or V2303M aggrecan G3 variants were in-
jected in running buffer (10 mM HEPES-HCl, 150 mM NaCl,
2 mM CaCl2, and 0.005% P20 [pH 7.5] at 25
C) into the ﬂow
cells at concentrations ranging between 1.5 nM and 50 nM,
and duplicate measurements were made at each concentration.
The injections were at a ﬂow rate of 50 ml/min, which we previ-
ously have shown prevents mass transfer limitations for these
interactions.23 The ligand surfaces were regenerated by injection
of a 300 ml pulse of 20 mM EDTA and 1.5 M NaCl in running
buffer between each experiment. For conﬁrmation of the results,
control experiments were performed in the reverse orientation
with wild-type or V2303M aggrecan G3 variants Lt, LCt, and
E1E2LCt immobilized on a CM5 sensor chip (250–1700 RU im-
mobilized). Fibulin-1A, ﬁbulin-2, and a recombinant fragment
comprising FnIII repeats 3–5 of tenascin-R were injected (in
duplicate) at 50 ml/min over the surfaces at concentrations
ranging from 1.5–50 nM. Surfaces were regenerated by four
consecutive 300 ml injections of 20 mM EDTA and 1.5 M NaCl
in running buffer. After X and Y normalization and subtraction
of blank curves, the association (kass) and dissociation (kdiss) rate
constants were determined simultaneously via Marquardt-
Levenberg global curve ﬁts to the equation for 1:1 Langmuir
binding in the BIAevaluation 4.1 software (BIAcore). The equi-
librium dissociation constant (KD) of each binding reaction
was calculated from these values.Extraction and Puriﬁcation of Aggrecan
from Cartilage
Articular cartilage was obtained from the tibial plateau and
femoral condyles of a 44-year-old female patient who had familialan unaffected family member (top trace), show heterozygosity
for a G-to-A transition in the ACAN gene.
(C) The c.6907G > A mutation results in the replacement of the
highly conserved Val2303 residue in the aggrecan C-type lectin
(CLD) repeat with a Met residue.
(D) The Val2303 residue (arrow) is located in a beta strand under-
lying the CLD ligand-binding site, and its side chain is buried
in the tightly packed hydrophobic core of the CLD repeat. The
location of the CLD ligand-binding surface is indicated by an
arrowhead.
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Table 1. Primers Used for ACAN Gene Sequencing
NM_001135.2 Exon NM_013227.2 Exon Amplicon Primera Primer sequence (50-30) TM Amplicon Length
1 UTR 1 UTR W1a -
1 UTR 1 UTR W1b W1b F GGAGTCCGCAACCCAGCAG 58C 248 bp
W1b R TGCAGTCTCAGTCCCGTTCC
2 2 2 2F ATCTCACAAACCACGTGCAG 58C 403 bp
2R GGGTGCTATCCCATCACAGT
3 3 3 3F GAGTGCATTGCTGGAAGGAT 58 536 bp
3R CGGAGACTGCTCTGGTTCTT
4 4 4 4F TCGGTGATCAGAGACTGTGC 58C 417 bp
4R GTTTGGGATGGGTCATTGAG
5 5 5 5F GAGGAGGATTCAAAGGCAGA 58C 405 bp
5R TGAGACCCTCTCCAAAGTGG
6 6 6 W6F AGGACTCCCAAGACCTCG 55C 443 bp
W6R CCCATTTTAGTGGCATGAAC
7 7 7 7F GCTGAGTACCCCTGAAATGG 55C 801 bp
7R TGTGCCTGCTTGATACAGAGA
8 8 8 8F GGCTACCAAGTGGGATTTCA 55C 525 bp
8R TCTGATGGGGAGAAATGACC
9 9 9 9F CAGGAGCCACCAGATCCTT 58C 520 bp
9R TTCAGTAGGAGAGCAGGCACTA
10 10 10 10F TGGTGAGGAGGGTTAGAGGA 55C 578 bp
10R AGAAGGATGACCTTGCCTTG
11 11 11 11F GGTGCCGATGGCTCTTACTA 58C 518 bp
11R CTGGGGAAACAGCACAAATC
12b 12 W12a W12a F AGTGGGGCAGAGTTAATAAAC 55C 256 bp
W12a R GGCTCCTCTGAGGGGAAC
W12b W12b F ATTCCCCTCAGTGGAGCTGT 65C 375 bp
W12b R TCACCAACCGTAGGAGTGC
13b 13 W12d W12d F GATTACATTTGTGGACACCAG 55C 382 bp
W12d R TCCTGCCTCTTGGGCTG
W12e W12e F TTTGGTGGAATCTGTAACCCAG 58C 403 bp
W12e R GGAGACTTTTCCACTGGAC
W12f W12f F CCCTGTGACACACACACC 58C 427 bp
W12f R TCCGCTGATTTCAGTCCTG
W12 g W12 g F CTCCCACGGCTTCTGGAG 58C 309 bp
W12 g R CTACCTAAGCACATTTAAAGGG
14 W13 W13 F GAGGTCTTGGAGGCCATGGTA 65C 262 bp
W13 R ACCTGGGGACCCTTTGGGGGA
EGF2c EGF2 14 14F GCAGCAACAGTTCTCAGG 58C 261bp
14R GCAGCAGTTAGTAACATTAGC
14 15 15 15F GAGTGGAAGCATGTGCAGAG 58C 433 bp
15R CTGCCTTCTGAAAGGTGAGG
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Table 1. Continued
NM_001135.2 Exon NM_013227.2 Exon Amplicon Primera Primer sequence (50-30) TM Amplicon Length
15 16 16 16F GAGAGGTGGCCCGAAGTG 55C 412 bp
16R CCCTGCCCTCAAGGGTTC
16 17 17 17F ATTCCCAGCAGTTTTTGTGC 55C 340 bp
17R GATCCTATCCTCCCCTGACC
18 W18 18F CCTCGGGTCACAACCAGC 55C 318 bp
18R GGAAGGCTGTGCTGGCAG
17 19 19 19F CCAAATCAGGAAAGCCGATA 55C 542 bp
19R CTTAACCCCTCCCCTTCTCC
a The sequences for primers labeled ‘‘W’’ were kindly provided by Gillian Wallis (University of Manchester, UK).
b Because of VNTR’s, only parts of exon 12 and 13 were sequenced.
c Primers for EGF2 modified from reference number 19.osteochondritis dissecans and was undergoing arthroplasty
because of severe OA. Cartilage was pulverized in liquid N2, and
aggrecan was extracted with GuHCl and puriﬁed by dissociative
CsCl gradient centrifugation as described.26
Mass Spectrometry
The aggrecan-containing D1 fraction was dialyzed into 25 mM
ammonium bicarbonate buffer (pH 7.8) and digested with endo-
proteinase GluC (at 24C overnight), and the resulting peptides
were separated on a mRPC C2/C18 reverse-phase HPLC column
in a SMART chromatography system (Pharmacia) with a gradient
of 0%–100% acetonitrile in 0.1% TFA. The elution times of the
peptides of interest (DCVVMIWHE and DCMVMIWHE) were
determined with GluC-digested recombinant wild-type and
V2303M mutant aggrecan G3 proteins. The fraction of the
GluC-digested patient aggrecan containing the peptides of interest
was analyzed by MALDI-TOF MS and ion trap MSMS. For MALDI-
TOF MS, the sample was mixed with 2,5-dihydroxybenzoic acid
(DHB) matrix, spotted onto an anchorchip target plate for
MALDI-TOF MS (Bruker Daltonics, Bremen, Germany), and
analyzed with a Bruker Reﬂex III apparatus. For corroboration of
the mass peaks, the patient sample was spiked with wild-type
andmutant peptides from recombinant aggrecan. For MSMS anal-
ysis, the fraction of interest was injected into anHCT ion trapmass
spectrometer controlled by HyStar software, and spectra were pro-
cessed with Data Analysis software (Bruker Daltonics). Selected
Tandem MS spectra were checked with BioTools (Bruker). The
mass spectrometer was programmed to perform tandemMS exper-
iments only on peptide ions relating to aggrecan V2303M muta-
tion. The following peptide ions were included on the basis
of observed masses in MALDI MS data; mutant DCMVMIWHE,
m/z ¼ 610.75 Da (þ2), wild-type DCVVMIWHE, m/z ¼ 594.76 Da
(þ2), mutant NWRPNQPDNFFAAGEDCMVMIWHE, m/z ¼ 988.76
Da (þ3), and wild-type NWRPNQPDNFFAAGEDCVVMIWHE,
m/z ¼ 978.10 Da (þ3).Results
To identify the genetic defect causing familial osteochon-
dritis dissecans, we performed a genome-wide multipoint
linkage analysis on a Swedish family displaying the diseaseThe Americaover ﬁve generations. The clinical details of the family
have been described.4 We obtained evidence for linkage
to the disease with chromosome 15q26markers (Figure 1E)
showing a peak lod score at D15S127 (TLOD 6.36, theta
0.00; Figure 1F). Reﬁned mapping revealed that all affected
individuals shared a 10.5 Mb haplotype restricted by the
polymorphic markers D15S205 and D15S130 (Figure 1G).
The candidate region spans approximately 100 genes
(NCBI Map Viewer), including the ACAN gene, which
encodes aggrecan.
Because of the fundamental importance of aggrecan for
skeletal development and cartilage function, we consid-
ered ACAN to be a prime candidate gene for familial osteo-
chondritis dissecans. We sequenced the complete coding
region of the ACAN gene, including the alternatively
spliced EGF2 repeat19 (absent from the two aggrecan iso-
forms in GenBank: NM_001135 and NM_013227) but
not including parts of the VNTR-region of exon 12 and
exon 13, in two affected and two unaffected family
members. This revealed a G-to-A transition in exon 17 in
the affected individuals (c.6907G > A in aggrecan isoform
2, GenBank NM_013227.2), predicting a Val-to-Met amino
acid substitution of the coding sequence (p.V2303M)
(Figure 2B). Exon 17 was sequenced in 49 additional family
members, and the V2303M mutation was identiﬁed in all
19 affected individuals. The mutation was absent in all
unaffected familymembers. Denaturing high-performance
liquid chromatography (dHPLC, not shown) showed that
the transition was also excluded on 230 control chromo-
somes derived from unrelated healthy Swedes.
The Val residue that is mutated in familial osteochondri-
tis dissecans is located in the C-type lectin domain (CLD)
of the aggrecan G3 domain, a protein region that is highly
conserved between different species and that is involved in
organizing the aggrecan network through interactions
with other cartilage ECMmolecules.11–15,23,27 Themutated
Val residue is strictly conserved between species
(Figure 2C) and is located in one of the beta strands at
the known ligand-interaction site of the aggrecan CLDn Journal of Human Genetics 86, 126–137, February 12, 2010 131
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Figure 3. The V2303M Mutation Affects Aggrecan CLD Interactions
(A) Domain organization of three different splice variants of the wild-type aggrecan G3 domain, and the corresponding V2303M vari-
ants, produced as recombinant proteins in human embryonic kidney 293 cells.
(B) Ni2þ-nitriloacetic acid (NiNTA)-agarose precipitation of His-tagged recombinant proteins from conditionedmedium containing fetal
calf serum. Bovine ﬁbulin-1, a known aggrecan CLD ligand present in serum, copuriﬁedwith the wild-type recombinant G3 variants, but
not with the V2303M proteins. The identity of ﬁbulin-1 and the recombinant proteins was veriﬁed by MALDI-TOF mass spectrometry
(not shown).
(C) Solid-phase competition binding assay. Microtiter plate wells were coated with the FnIII 3-5 fragment of the CLD ligand tenascin-R,
and alkaline phosphatase-tagged aggrecanCLDwas allowed to bind in the presence of varying concentrations (0.3–1000 nM) of compet-
itor proteins (open circles, wild-type E1E2LCt; ﬁlled triangles, V2303M E1E2LCt). Each data point represents the average of ﬁvemeasure-
ments; error bars show standard deviation.
(D) Surface plasmon resonance interaction analysis. The sensorgrams show overlays of duplicate samples of the different recombinant
aggrecan G3 variants. The lowest traces in each sensorgram show injections of running buffer alone. Samples (at 1.5 to 50 nM in HEPES-
buffered saline containing 2 mM CaCl2) were injected for 4 min at 50 ml/min over a BIAcore sensor chip coupled with the CLD ligand
ﬁbulin-2, followed by injection of running buffer. The binding and dissociation of the G3 variants was registered in a BIAcore 2000
instrument. All wild-type G3 proteins showed strong binding and slow dissociation, whereas no or insigniﬁcant binding of the
V2303M variants was observed.(labeled Val100 in Lundell et al.28); its side chain is buried
within the tightly packed hydrophobic core of the protein
fold (Figure 2D).28 Molecular structure modeling suggested
that the V2303M substitution leads to a conformational
change of the aggrecan CLD (not shown).
To determine whether the V2303M substitution has any
effects on aggrecan G3 domain secretion and/or interac-
tions, we produced wild-type andmutant human aggrecan
G3 domains as recombinant proteins. Because the EGF and
CRP repeats of the G3 domain are subject to alternative
splicing,23 we produced three different splice variants of
the G3 domain with and without the V2303M substitution132 The American Journal of Human Genetics 86, 126–137, February(Figure 3A). All three mutated G3 variants were expressed
and secreted by the human embryonic kidney 293 cell
line, although the protein yields of the shorter mutant
recombinant proteins appeared to be lower than those of
the corresponding wild-type proteins (Figure 3B). The ag-
grecan CLD is known to interact with ECM proteins in the
tenascin,13,14,23 ﬁbrillin,27 and ﬁbulin12,15 families. Inter-
estingly, initial His-tag afﬁnity precipitation of the re-
combinant proteins from conditioned medium via NiNTA
beads resulted in copuriﬁcation of the CLD ligand ﬁbulin-1
with all three wild-type G3 variants but not with any of the
V2303M mutated G3 domains (Figure 3B). The identity of12, 2010
Table 2. Aggrecan G3 Domain Affinities for C-type Lectin Ligands
G3 Variant
KD (nM) for
Tenascin-Ra
KD (nM) for
Fibulin-1b
KD (nM) for
Fibulin-2c
E1E2LCt 0.08 7.7 0.11
V2303M E1E2LCt 0.67 -d 43.6
LCt 0.26 38.1 0.93
V2303M LCt 2080 -d -d
Lt 0.26 17.9 1.18
V2303M Lt 166 -d -d
Aggrecan G3 variants were injected over ligand proteins immobilized on a
BIAcore CM5 sensor chip by amine coupling.
a Tenascin-R FnIII repeats 3–5.
b Fibulin-1 domain II.
c Fibulin-2 domain II.
d No binding.ﬁbulin-1 as well as that of the recombinant proteins was
veriﬁed by MALDI-TOF mass spectrometry (not shown).
The recombinant proteins were then puriﬁed to apparent
homogeneity by His-tag metal-chelation-afﬁnity, ion-
exchange, and gel-ﬁltration chromatography. Using a
solid-phase inhibition assay, we found that the afﬁnity
for tenascin-R was decreased in the mutated G3 domain
compared to the wild-type (Figure 3C). Analyses of interac-
tions by surface plasmon resonance using a BIAcore veri-
ﬁed that tenascin-R, ﬁbulin-1, and ﬁbulin-2 binding was
affected for all V2303M mutated G3 splice variants (Fig-
ure 3D), which all showed weakened afﬁnities or complete
loss of interaction (Table 2). Taken together, this clearly
demonstrates that the familial osteochondritis dissecans-
associated V2303M substitution affects normal aggrecan
G3 domain function.
To determine whether aggrecan containing the V2303M
mutation is actually produced and secreted in vivo, we
studied proteoglycans from articular cartilage of an affected
family member undergoing knee arthroplasty. After guani-
dine hydrochloride extraction, aggrecan was puriﬁed by
CsCl density gradient centrifugation. After digestion with
endoproteinaseGluC, the resulting peptideswere separated
by reverse-phase HPLC, and the fractions were analyzed by
mass spectrometry (Figure 4A).MALDI-TOFMS showed the
presence of peptides with both wild-type sequence and
the V2303M sequence, as we corroborated by spiking the
samplewith peptides fromwild-type andmutated recombi-
nant CLD (Figure 4B). To verify the peptide sequences, we
analyzed the sample further by ion trap MSMS and
conﬁrmed the presence of both the wild-type (Figure 4C)
and the V2303M (Figure 4D) aggrecan sequences.
We quantiﬁed the total amount of proteoglycan in the
extracts (in principle representing aggrecan) and in aggre-
can puriﬁed via CsCl density-gradient centrifugation by
using Alcian blue precipitation.29 In this procedure the
acid conditions and the elevated ionic strength provides a
focus on the sulfate groups. The proteoglycan contents of
a control extract from osteoarthritic knee cartilage (pooledThe Americafrom ten individuals) and of the patient extract, as well as
of puriﬁed aggrecan (D1 fraction) from the OA cartilage
pool and the patient, were found to be similar (26.8 versus
24.8 mg/g and 13.1 versus 14.0 mg/g, respectively), indi-
cating that there is nomajor alteration in aggrecan secretion
or glycosaminoglycan sulfation in the patient tissue.Discussion
These results provide a molecular explanation for auto-
somal-dominant familial osteochondritis dissecans. In
addition to osteochondritis dissecans, the clinical features
of this disease include premature OA and mild, dispropor-
tionate short stature.4 All of these symptoms are consistent
with an impaired matrix assembly and function due to the
aggrecan G3 dysfunction.
The etiology of sporadic osteochondritis dissecans is
likely to be multifactorial.30 Suggested contributing factors
include trauma and microfractures resulting from the
cumulative damage of repetitive stress or injury and/or
fragility of the cartilage and bone. Disturbance of the endo-
chondral ossiﬁcation might cause areas of local ischemic
necrosis, predisposing the joint to osteochondritis disse-
cans after microtrauma.31 Finally, the formation of an
abnormal cartilage might predispose individuals to osteo-
chondritis dissecans. This might result from an altered
networking of molecules in the cartilage. Our results
show that perturbed function in a domain of aggrecan in-
teracting with other extracellular matrix molecules is a key
factor in the etiology of familial osteochondritis dissecans.
Both the sporadic and familial forms of osteochondritis
dissecans are associated with secondary OA when lesions
occur after closure of the epihyseal growth plate.2 In
contrast, lesions occurring before closure of the growth
plate normally heal spontaneously without secondary
OA development in patients with sporadic osteochondritis
dissecans.2 In patients with familial osteochondritis disse-
cans, however, lesions before growth plate closure are asso-
ciated with secondary OA.4 Interestingly, early-onset OA
is part of the phenotype in the family under study. Prema-
ture OA is part of the pathology associated with many
mutations affecting cartilage ECM assembly or stability,
e.g., in Stickler syndrome type I [MIM 108300] (COL2A1
[MIM 120140]), type II [MIM 604841] (COL11A1 [MIM
120280]), and type III [MIM 184840] (COL11A2 [MIM
120290]) and in multiple epiphyseal dysplasia
([MIM 132400] (COL9A1 [MIM 120210], COL9A2 [MIM
120260], COL9A3 [MIM 120270], COMP [MIM 600310],
and MATN3 [MIM 602109]).32 Because sporadic osteo-
chondritis dissecans before growth arrest does not lead to
OA, the premature OA associated with familial osteochon-
dritis dissecans is consistent with a disorganized and weak-
ened cartilage ECM caused by loss of G3 interactions in the
V2303M aggrecan.
A characteristic clinical feature of familial osteochon-
dritis dissecans is disproportionate short stature.4 Then Journal of Human Genetics 86, 126–137, February 12, 2010 133
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Figure 4. Aggrecan Containing the V2303M Mutation Is Produced and Present in Patient Cartilage
(A) Schematic representation of the extraction, puriﬁcation, and analysis of aggrecan from articular cartilage obtained after knee-replace-
ment surgery in a patient with familial osteochondritis dissecans.
(B) Top: MALDI-TOF mass spectrometry of trypsin digests identiﬁed peptides from both wild-type (DCVVMIWHE, 1188.51 Da) and
Val > Met (DCMVMIWHE, 1220.48 Da) aggrecan in C2/C18 fraction 17 from the patient cartilage extract. Middle: Patient cartilage
extract with added wild-type recombinant protein. Bottom: Patient cartilage sample with added recombinant mutant protein.
(C and D) Ion trapMSMS analysis of C2/C18 fraction 17 from the patient sample conﬁrmed the presence and sequence of both wild-type
(C) and V2303M (D) aggrecan in patient cartilage. Wild-type DCVVMIWHE, m/z ¼ 594.76 Da (þ2); mutant DCMVMIWHE,
m/z ¼ 610.75 Da (þ2).aggrecan gene has been identiﬁed by genome-wide asso-
ciation analysis as a locus inﬂuencing adult height.33
Mutations in the aggrecan gene that result in skeletal
phenotypes have been identiﬁed in several species.34–38
Most described aggrecan mutations are either null (cmd-
Bc and Dexter Bulldog cattle BD2) or functional null134 The American Journal of Human Genetics 86, 126–137, February(cmd, nanomelia, Dexter Bulldog cattle BD1, and spondy-
loepiphyseal dysplasia type Kimberley [SEDK, (MIM
608361)]). The latter mutations result in premature stop
codons with several downstream introns and show low-
ered aggrecan mRNA levels.39,40 In the case of ACANBD1,
it has been veriﬁed that this is due to nonsense mediated12, 2010
decay,34 which is likely the case for all the functional null
mutations. The remaining mutant aggrecan mRNA might
be translated, but secretion of truncated aggrecan is pre-
vented by proteosomal degradation.16 When homozy-
gous, the aggrecan null and functional null mutations
result in lethal skeletal dysplasias. In the heterozygous
state, these mutations lead to aggrecan haploinsufﬁciency
and dwarﬁsm phenotypes, and in the case of SEDK, this
is associated with early-onset OA in weight-bearing
joints. 35,41 Aggrecan provides swelling pressure to the
cartilage tissue ECM through osmotic attraction of water
by counter ions bound to the thousands of sulfate and
carboxyl groups carried on the glycosaminoglycan chains
of each proteoglycan molecule. Thus, skeletal phenotypes
similar to aggrecan deﬁciency also result from mutations
affecting glycosaminoglycan sulfation.42 Our data are
consistent with a normal V2303M aggrecan secretion,
and we have no reason to believe that sulfation is
affected. We suggest that the loss of G3 interactions in
the mutant might contribute to a disorganized ECM in
the growth plate and thus lead to decreased long bone
growth in the affected individuals.
The importance of the G3 interactions for skeletal
development is supported by the recent identiﬁcation
of an additional missense mutation (D2267N) in the
human aggrecan CLD.43 The D2267N mutation results
in recessive spondyloepimetaphyseal dysplasia (MIM
612813), and homozygous individuals display extreme
short stature, brachydactyly, and craniofacial abnormali-
ties. Unlike patients with familial osteochondritis disse-
cans, these patients showed no orthopedic complications
or signs of OA. Mild proportionate short stature was re-
ported for two individuals heterozygous for the D2267N
mutation.
The D2267N mutation obliterates one of the two
calcium coordinations provided by this residue and also
generates a novel site for N-linked glycosylation, which
at least in recombinant G3 proteins is glycosylated. This
might affect aggrecan CLD interaction with ECM ligands
such as tenascins or ﬁbulins, and experiments showed low-
ered total binding and altered kinetics in D2267N variant
CLD interactions with tenascin-C. The retained tenascin-
C binding of the D2267N variant proteins suggests that
this mutation is less disruptive to CLD function than the
V2303M mutation, which showed strong effects on CLD
ligand binding. Nonetheless, the severe phenotype
observed in the D2267N homozygous individuals con-
ﬁrms the importance of CLD interactions for aggrecan
function.
The dominant phenotype seen in the heterozygous
V2303M individuals is consistent with a critical role of
the aggrecan G3-domain interactions in regulating matrix
assembly. There was no signiﬁcant difference in the levels
of mutated and wild-type aggrecan in joint cartilage from
a V2303M patient, as evidenced by the similar signals
upon mass spectrometry (Figure 4B). There was, moreover,
no apparent perturbation in sulfation of aggrecan from theThe Americapatient given that the reactivity in the Alcian blue assay
was normal. The pronounced phenotype of the heterozy-
gous individuals therefore indicates a dominant negative
role of the mutated molecules, which might compromise
the organization and interaction of matrix molecules
that are crucial for normal function in a load-bearing tissue
such as cartilage.Acknowledgments
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